Lilly Pulls The Plug On Next-Gen Antipsychotic
This article was originally published in The Pink Sheet Daily
Executive Summary
With one Phase III trial failed and a second halted for futility, Eli Lilly calls it quits on pomaglumetad methionil, a compound the pharma had hoped would succeed blockbuster antipsychotic Zyprexa, marking the end of the road for a pioneering compound in the effort to drug metabotropic glutamate receptors (mGluRs), a promising class for CNS therapies.
You may also be interested in...
Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure
Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.
Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure
Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.
Cruel Summer: High-Profile Trial Failures Dominate R&D News Flow
As the summer of 2012 wears on, an outpouring of negative clinical trial news for high-profile new drug candidates has made the season more a time of doldrums than of fun in the sun for big pharma.